Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (TAKE-IT)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence
About this trial
This is an interventional treatment trial for Leukemia, Myelogenous, Chronic, BCR-ABL Positive focused on measuring adherence, chronic myeloid leukemia, tyrosine kinase inhibitors
Eligibility Criteria
Inclusion Criteria:
Patients with chronic phase chronic myeloid leukemia (CP-CML), aged 18 years or older
- CP-CML defined as: Medical history of cytogenetically confirmed CP-CML defined as the presence of the Philadelphia chromosome on bone marrow aspirates (a minimum of 20 metaphases is required; FISH cannot be used). If Philadelphia chromosome was negative or if cytogenetic results were not available, BCR-ABL-positive CML patients can be included.
- At least 3 months of TKI treatment (imatinib, dasatinib or nilotinib) before study initiation.
Exclusion Criteria:
- Current or prior accelerated/blast phase or stem cell transplant
- Participation in another interventional study
- Pregnancy
Sites / Locations
- Soroka Medical Center
- Rambam Medical Center
- Meir Medical Center
- Rabin Medical Center
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Run-in period
Adherence-encouraging period
First 3 months of study during which adherence will be measured for each consecutively included study subject, but no intervention will be performed. Patient will receive routine treatment for CML according to the physician discretion.
Months 4 to 9 of study during which adherence will be measured for each consecutively included study subject, while implementing adherence-encouraging interventions: adherence-encouraging interventions - Group meetings adherence-encouraging interventions - Individual meetings adherence-encouraging interventions - Monthly phone calls Patient will receive routine treatment for CML according to the physician discretion.